New pill plus immunotherapy targets Hard-to-Treat cancers

NCT ID NCT07446049

Not yet recruiting Disease control Sponsor: Convalife (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growth. About 180 adults aged 18 to 75 with various cancers (like gastric, lung, or breast) who have not responded to standard treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CVL237 tablets and serplulimab injection
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that have a specific genetic change (PTEN loss), potentially slowing disease progression.
What could go wrong: This is an early-phase trial (Phase Ib/II) with only 180 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm endometrium neoplasm gastric neoplasm lung neoplasm ovarian cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS PTEN LOSS OR LOW EXPRESSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.